OUR STORY

Tessa Therapeutics is founded on over three decades of research and development by our Scientific Co-Founder, Dr. Malcolm K Brenner, and his team at Baylor College of Medicine. Leveraging the potential of the body’s natural anti-viral immune response as a therapy for cancer treatment, Tessa is emerging with a new approach to cell therapy for hematologic malignancies and solid tumors.

Learn More

OUR SCIENCE

Tessa is combining the unique properties of Virus-Specific T cells (VSTs) and CD-30 Chimeric Antigen Receptors (CD30-CARs) to develop an allogeneic platform technology that gives us the potential to create next-generation cell therapies for the treatment of hematologic malignancies and solid tumors.

Learn More

OUR PIPELINE

Our robust clinical pipeline of autologous and allogeneic cell therapies includes two late-stage clinical studies for Hodgkin lymphoma and nasopharyngeal cancer.

Learn More

OUR OPERATIONS

Our global manufacturing and supply chain capabilities — enhanced by a new commercial-scale cGMP — will enable us to supply next-generation cell therapies that may potentially address the significant needs of the global oncology community.

Learn More
null

Our Story

null

Our Science

null

Our Pipeline

null

Our Operations

Feature News

Tessa at a Glance

200+ Employees Globally

Learn More >>

2 Late-stage Clinical Trials

Learn More >>

Global Site Network

Learn More >>

3 Research & Development Labs

Learn More >>

5 Strategic Partnerships

Learn More >>

Upcoming cGMP Manufacturing Facility

Learn More >>

Global Scientific Advisory Board & Key Opinion Leader Network

Learn More >>

3 Satellite Labs

Learn More >>
More About Tessa Therapeutics

Tessa on Twitter

Tessa Therapeutics @TessaImmunology
2 months ago
We are delighted to welcome Mr. Jeffrey H. Buchalter on board as CEO. He brings over 30 years of biopharmaceutical experience combining strong corporate leadership and extensive background in the development of therapeutics in oncology. Read more: https://t.co/hqXVvZTVXG https://t.co/7OBosaLfqt
View on Twitter
0
2
Tessa Therapeutics @TessaImmunology
4 months ago
We are pleased to announce that Tessa’s investigational CD30 CAR-T therapy has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA for the treatment of relapsed or refractory classical Hodgkin lymphoma. Read more here: https://t.co/rR5pJMZZ0f https://t.co/Rjp4NxhSau
View on Twitter
3
12
Follow Us on Twitter

Tessa’s Media Channel

In this latest interview, Dr Ramy Ibrahim from Parker Institute for Cancer Immunotherapy discusses some of the cellular immunotherapy breakthroughs we can anticipate this decade.

Watch Video